Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul 28;24(15):12100.
doi: 10.3390/ijms241512100.

New Ideas for the Prevention and Treatment of Preeclampsia and Their Molecular Inspirations

Agata Sakowicz  1 , Michalina Bralewska  1 , Magda Rybak-Krzyszkowska  2 , Mariusz Grzesiak  3   4 , Tadeusz Pietrucha  1
Affiliations
Review

New Ideas for the Prevention and Treatment of Preeclampsia and Their Molecular Inspirations

Agata Sakowicz et al. Int J Mol Sci. .

Abstract

Preeclampsia (PE) is a pregnancy-specific disorder affecting 4-10% of all expectant women. It greatly increases the risk of maternal and foetal death. Although the main symptoms generally appear after week 20 of gestation, scientific studies indicate that the mechanism underpinning PE is initiated at the beginning of gestation. It is known that the pathomechanism of preeclampsia is strongly related to inflammation and oxidative stress, which influence placentation and provoke endothelial dysfunction in the mother. However, as of yet, no "key players" regulating all these processes have been discovered. This might be why current therapeutic strategies intended for prevention or treatment are not fully effective, and the only effective method to stop the disease is the premature induction of delivery, mostly by caesarean section. Therefore, there is a need for further research into new pharmacological strategies for the treatment and prevention of preeclampsia. This review presents new preventive methods and therapies for PE not yet recommended by obstetrical and gynaecological societies. As many of these therapies are in preclinical studies or under evaluation in clinical trials, this paper reports the molecular targets of the tested agents or methods.

Keywords: anti-inflammatory agents; antioxidants; antithrombin III; apheresis; metformin; nitric oxide; nuclear factor kappa B; peptides; polyphenols; preeclampsia; probiotics; proton pump inhibitors; short interfering RNA; soluble fms-like tyrosine kinase 1; statins; vitamins.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The groups of agents adopted for the prevention and treatment of preeclampsia and their molecular inspirations, i.e.,: NFĸB inhibitors: aspirin, hydroxychloroquine, metformin, proton pump inhibitors, statins, sulfasalazine; inflammation inhibitors: aspirin, eculizumab, metformin, mesenchymal cells and their exosomes, probiotics, statins, sulfasalazine, vitamin D; oxidative stress inhibitors: aspirin, polyphenols, vitamin C, vitamin D, vitamin E; coagulation regulators: aspirin, antithrombin, hydroxychloroquine, mesenchymal cells and their exosomes; sFlt1 level regulators: apheresis, chimera of elastin like-polypeptide with vascular endothelial growth factor type A or type B, small interfering RNA particles; vessel construction regulators: aspirin, hydroxychloroquine, metformin, L-arginine, L-citrulline, proton pump inhibitors, statins, sulfasalazine. Legend: abbreviations: AA—arachidonic acid; ARG—arginine; AT1-AA—angiotensin II type 1 receptor autoantibody; ATR1—angiotensin II receptor type 1; C3a—complement component 3a; C5a—complement component 5a; COX—cyclooxygenase; ET1—endothelin 1; FVa—active coagulation factor Va; FVIIa—active coagulation factor VII; FXa—active coagulation factor Xa; ICAM 1—intracellular adhesion molecule type 1; IL6—interleukin 6; IL8—interleukin 8; NFĸB—nuclear factor kappa B; NO—nitric oxide; PAI-1—plasminogen activator inhibitor 1; PlGF—placenta growth factor; ROS—reactive oxygen species; sENG—soluble endoglin; sFlt1—soluble fms-like tyrosine kinase 1; TF—tissue factor; TGFβ—tumour growth factor beta; THX—thromboxane; TNFα—tumour necrosis factor alpha; VCAM 1—vascular adhesion molecule type 1, VEGFR1—vascular endothelial growth factor receptor type 1; VEGFR2—vascular endothelial growth factor receptor type 2; symbols: formula image process activation; formula image process inhibition; formula image the direction of common relationships between the analysed factors.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Collier A., Ris Y., Smith L.A., Karumanchi S.A. Review of the immune mechanisms of preeclampsia and the potential of immune modulating therapy. Hum. Immunol. 2021;82:362–370. doi: 10.1016/j.humimm.2021.01.004. - DOI - PMC - PubMed
    1. Tanner M.S., Davey M.A., Mol B.W., Rolnik D.L. The evolution of the diagnostic criteria of preeclampsia-eclampsia. Am. J. Obstet. Gynecol. 2022;226:S835–S843. doi: 10.1016/j.ajog.2021.11.1371. - DOI - PubMed
    1. Robillard P.-Y., Boukerrou M., Dekker G., Scioscia M., Bonsante F., Boumahni B., Iacobelli S. Risk Factors for Early and Late Onset Preeclampsia in Reunion Island: Multivariate Analysis of Singleton and Twin Pregnancies. A 20-Year Population-Based Cohort of 2120 Preeclampsia Cases. Reprod. Med. 2021;2:131–143. doi: 10.3390/reprodmed2030014. - DOI
    1. ACOG Practice Bulletin no. 222. Clinical Management Guidelines for Obstetrician–Gynecologists Gestational Hypertension and Preeclampsia. Obstet. Gynecol. 2020;135:e237–e260. doi: 10.1097/AOG.0000000000003891. - DOI - PubMed
    1. González-Ramos R., Rocco J., Rojas C., Sovino H., Poch A., Kohen P., Alvarado-Díaz C., Devoto L. Physiologic activation of nuclear factor kappa-B in the endometrium during the menstrual cycle is altered in endometriosis patients. Fertil. Steril. 2012;97:645–651. doi: 10.1016/j.fertnstert.2011.12.006. - DOI - PubMed

Substances

Grants and funding

This research received no external funding.